Search results for "Stomach"

showing 10 items of 421 documents

Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.

1998

BACKGROUND Expression of nm23 has been shown to be inversely correlated with the metastatic potential of several human cancers. In the current study, the expression and prognostic impact of nm23 was immunohistochemically studied in 413 curatively resected gastric carcinomas. METHODS Tumor sections of the 413 gastric carcinomas were stained with a polyclonal antibody that was raised against the nm23-H1/NDP kinase A, which is identical to the nm23-H1 gene product. RESULTS Expression of nm23 was detected in 84.5% (n = 349) of all tumors, in the majority of cases (71.2%) causing a homogeneous staining reaction in more than 75% of tumor cells. Expression of nm23 was positively correlated with th…

AdultMaleCancer ResearchMetastasisAntigens NeoplasmStomach NeoplasmsLymphatic vesselBiomarkers TumorMedicineHumansLymph nodeAgedMonomeric GTP-Binding ProteinsAged 80 and overbusiness.industryStomachCarcinomaCancerMiddle AgedNM23 Nucleoside Diphosphate Kinasesmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyTumor progressionNucleoside-Diphosphate KinaseCancer researchAdenocarcinomaImmunohistochemistryFemalebusinessCarcinoma Signet Ring CellTranscription FactorsCancer
researchProduct

Sensing gastric cancer via point‐of‐care sensor breath analyzer

2021

Background Detection of disease by means of volatile organic compounds from breath samples using sensors is an attractive approach to fast, noninvasive and inexpensive diagnostics. However, these techniques are still limited to applications within the laboratory settings. Here, we report on the development and use of a fast, portable, and IoT-connected point-of-care device (so-called, SniffPhone) to detect and classify gastric cancer to potentially provide new qualitative solutions for cancer screening. Methods A validation study of patients with gastric cancer, patients with high-risk precancerous gastric lesions, and controls was conducted with 2 SniffPhone devices. Linear discriminant an…

AdultMaleCancer ResearchValidation studymedicine.medical_specialtyvolatile organic compoundPoint-of-Care SystemsBiosensing TechniquesSensitivity and Specificity03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingbreath analyzerStomach NeoplasmsCancer screeningmedicineHumansNanotechnology030212 general & internal medicinePoint of careAgedAged 80 and overbusiness.industrygastric cancerscreeningCancerpersonalizedDiscriminant AnalysisGastric lesionsMiddle Agedmedicine.diseaseLinear discriminant analysisprecancerous lesion3. Good healthBreath analyzerOncologyBreath Tests030220 oncology & carcinogenesisArea Under CurveCase-Control Studies/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleRadiologyInternet of ThingsbusinessPrecancerous ConditionsCancer
researchProduct

Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule

1994

A phase II trial of etoposide (100 mg/m2) on days 4, 5, 6, doxorubicin (Adriamycin, 20 mg/m2) on days 1, 7, and cisplatin (30 mg/m2) on days 2, 8 (EAP) was carried out in order to reduce toxicity associated with a full-dose EAP regimen for advanced and/or metastatic gastric adenocarcinoma. Out of 21 evaluable patients, 2 (10%) had a complete response (CR), 7 (33%) had a partial response (PR), 4 (20%) showed no change and 8 progressed (38%). The mean duration of response (CR+PR) was 8.4+ months. Survival of the whole group was 7.5+ months. Treatment was quite well tolerated by most patients on an outpatient basis. Grade 3 vomiting and leukopenia were seen in 30% and 35% of cases respectively…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdenocarcinomaGastroenterologyDrug Administration ScheduleStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyEtoposideAgedEtoposideCisplatinChemotherapyLeukopeniabusiness.industryStomachGeneral MedicineMiddle Agedmedicine.diseaseEAPSurgeryRegimenmedicine.anatomical_structureOncologyDoxorubicinVomitingAdenocarcinomaFemaleCisplatinmedicine.symptomGastric cancerbusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Descriptive Epidemiology of Stomach Cancer in Ragusa, Sicily, 1981–1988

1992

An epidemiologic study was carried out on 475 incident cases of gastric cancer registered by the Ragusa Cancer Registry (Sicily) between 1981 and 1988. Distribution by sex, age, subsite, year of incidence, and survival was investigated. A reduction of incidence and mortality between 1981–84 and 1985–88 was observed in both sexes, and was more evident in males than in females. Survival was not significantly different for cancers of the various subsites.

AdultMaleCancer Researchmedicine.medical_specialtyEpidemiologic studyGastroenterologySex FactorsStomach NeoplasmsInternal medicineHumansMedicineStomach cancerSicilyAgedAged 80 and overbusiness.industryIncidenceIncidence (epidemiology)Age FactorsCancerGeneral MedicineMiddle AgedDescriptive epidemiologymedicine.diseaseSurvival AnalysisCancer registryOncologyFemalebusinessDemographyTumori Journal
researchProduct

How do international gastric cancer prevention guidelines influence clinical practice globally?

2020

Clinical guidelines recommend particular approaches, including 'screen-and-treat' strategy for Helicobacter pylori, to prevent gastric cancer. However, little of this is implemented in clinical practice. The aim of the study was to identify barriers to implementation of international guidelines. A web-based questionnaire distributed globally to specialists in the field. Altogether 886 responses from 75 countries were received. Of the responders, 570 (64%) were men of mean age 47 years. There were 606 gastroenterologists and 65 epidemiologists among the responders. Altogether, 79.8% of the responders disagreed that the burden of gastric cancer is a diminishing problem. 'Screen-and-treat' str…

AdultMaleCancer Researchmedicine.medical_specialtyEpidemiologyPopulationMEDLINEHelicobacter Infections03 medical and health sciencesYoung Adult0302 clinical medicineSDG 3 - Good Health and Well-beingStomach NeoplasmsSurveys and QuestionnairesmedicineHumans030212 general & internal medicinePractice Patterns Physicians'educationEarly Detection of CancerAgedAged 80 and overeducation.field_of_studybiologyHelicobacter pyloribusiness.industryGastric cancer preventionUpper endoscopyPublic Health Environmental and Occupational HealthCancerInternational AgenciesHelicobacter pyloriMiddle Agedmedicine.diseasebiology.organism_classificationPrognosis3. Good healthClinical PracticeVaccinationSurvival RateOncology030220 oncology & carcinogenesisFamily medicinePractice Guidelines as Topic/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalebusinessEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

1990

Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the liver. No response was seen in patients with bone, lung or noda…

AdultMaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentPhases of clinical researchAdministration OralTegafurGastroenterologyStomach NeoplasmsInternal medicinemedicineCarcinomaHumansAgedTegafurChemotherapyGastrointestinal tractbusiness.industryStomachMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureOncologyVomitingDrug EvaluationFemalemedicine.symptombusinessColorectal Neoplasmsmedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in…

2005

An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m(-2), LV 500 mg m(-2), 24-h 5-FU 2000 mg m(-2), and ELF comprised three once-daily doses of etoposide 120 mg m(-2), LV 300 mg m(-2), 5-FU 500 mg m(-2). In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classLeucovorinPhases of clinical researchNeutropeniaAdenocarcinomaIrinotecanAntimetaboliteGastroenterologygastricStomach NeoplasmsInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans5-fluorouracilStomach cancerEtoposidePeritoneal NeoplasmsAgedEtoposideNeoplasm StagingLevoleucovorinbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgerymetastaticIrinotecanELFTreatment OutcomeOncologyTolerabilityFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilbusinessILFmedicine.drugBritish Journal of Cancer
researchProduct

Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allog…

2019

Intestinal graft-versus-host disease (GvHD) is a potentially life-threatening condition after allogenic hematological stem cell transplantation (alloHSCT). Although efforts have been made to determine the best sites for endoscopic biopsies, an approach involving all accessible anatomical regions is lacking. We investigated 22 complete biopsy series, each comprising biopsies from 10 different sites of the upper and lower intestine from 21 patients. The majority of biopsies investigated revealed histological signs of acute GvHD. The highest incidence and most advanced grades of acute GvHD were found in the right colon and terminal ileum. We detected significant correlations between crypt or g…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBiopsyGraft vs Host DiseaseIleumApoptosisHematopoietic stem cell transplantationDiseaseGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansTransplantation HomologousGrading (tumors)Agedbusiness.industryStomachHematopoietic Stem Cell TransplantationEndoscopyHematologyMiddle Agedmedicine.diseaseTransplantationPatient Outcome Assessmentsurgical procedures operativemedicine.anatomical_structureGraft-versus-host diseaseOncology030220 oncology & carcinogenesisHematologic NeoplasmsFemaleStem cellbusinessImmunosuppressive Agents030215 immunologyLeukemialymphoma
researchProduct

The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients

2015

Background Proton pump inhibitors (PPIs) are among the most misused drugs both at the community and hospital level. Recently, possible risks have been underscored, suggesting the importance of limiting PPI use to proven indications. Objective To survey the appropriateness of PPI use in a University hospital in Italy. Setting Azienda Ospedaliera Universitaria Policlinico ‘P. Giaccone’, in Palermo, Italy. Method A one day-observational study, reviewing patients’ medical records to identify treatments with PPIs and the indications for their use. After discharge, a subgroup of the cohort was followed up to assess the continuation of therapy at home. Appropriateness was evaluated according to th…

AdultMaleDrug UtilizationDrugmedicine.medical_specialtyIcu patientsmedia_common.quotation_subjectPharmaceutical ScienceInappropriate PrescribingPharmacyPharmacyProton pump inhibitorToxicologyHospitals UniversityHospitalmedicineDrug utilizationHumansPharmacology (medical)Stomach UlcerMedical prescriptionIntensive care medicineAgedmedia_commonPharmacologybusiness.industryMedical recordStress ulcerProton Pump InhibitorsMiddle Agedmedicine.diseasePatient DischargeHospitalizationTherapeutic appropriateneItalyPractice Guidelines as TopicCohortSettore BIO/14 - FarmacologiaFemaleGuideline Adherencebusiness
researchProduct

Polymorphisms of microRNA target genes

2016

AIM To evaluate associations between miRNA target genes IL12B, INSR, CCND1 and IL10 polymorphisms and gastric cancer (GC) in European population. METHODS Gene polymorphisms were analyzed in 508 controls and 474 GC patients from 3 tertiary centers in Germany, Lithuania and Latvia. Controls were patients from the out-patient departments, who were referred for upper endoscopy because of dyspeptic symptoms and had no history of previous malignancy. Gastric cancer (GC) patients had histopathological verification of gastric adenocarcinoma. Genomic DNA was extracted using salting out method from peripheral blood mononuclear cells. IL12B T>G (rs1368439), INSR T>C (rs1051690), CCND1 A>C (rs7177) and…

AdultMaleGenotypeInterleukin-12 Subunit p40LithuaniaMiddle AgedCase Control StudyLatviaPolymorphism Single NucleotideSingle-nucleotide polymorphismsReceptor InsulinInterleukin-10Antigens CDStomach NeoplasmsCase-Control StudiesGermanyLeukocytes MononuclearHumansRegression AnalysisCyclin D1FemaleTarget genesGastric cancerAgedmiRNAWorld journal of gastroenterology
researchProduct